arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

download Export Data

Conexeu Sciences Inc.

CNXU

$2.11 ▼ -0.08 (-3.43%) at close

8 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

insights

Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on CNXU.

Market Cap $56.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -131.4% ↘

FCF / Share $-0.25

Trailing P/E —

Price / Book 9.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-7.73M

↓ -494.9% —

FCF / Share Free cash flow per share

$-0.25

↓ -519.2% —

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
EPS Growth YoY (%)	-222.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-120.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-494.9% Weak Weak Year-over-year change in net income	-403.1% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-519.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	0.44x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Return on Invested Capital (%)	-131.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-33.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	-78.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-258.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-107.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-29.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—
Return on Common Equity (%) (%)	-132.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-980%)	-32.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-313%)	—	—	-78.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-623%)	-259.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1828%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Interest Coverage (x)	—	—	—	—	-30177.23x Weak Weak Operating income divided by interest expense Optimal: > 5x	-330.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-1.97M	$-6.85M	—	$-4.81M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Basic EPS, GAAP (USD)	$-0.29	$-0.11	—	—	$-0.09	$-0.05	—	—
Free Cash Flow per Share (USD)	$-0.25	—	—	—	$-0.04	—	—	—
Book Value per Share (USD)	$0.21	$0.34	—	$0.39	$0.12	$0.02	—	—
Tangible Book Value per Share (USD)	$0.21	$0.34	—	$0.39	$0.12	$0.02	—	—
Basic Weighted Avg Shares (shares)	26.97M	20.57M	—	—	14.10M	9.51M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Working Capital (USD)	$5.48M	—	—	$7.12M	—	—	—	—
Total Equity (USD)	$5.85M	$7.20M	$6.83M	$7.35M	$1.65M	$176.75K	$570.48K	$94.96K

📋 What is driving earnings? 3 metrics

Metric	Q3 FY2026 Jul 31, 2026 10-Q ↗	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-Q ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Feb 1, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-Q ↗
Depreciation Expense (USD)	$5.48K	—	—	—	$2.30K	—	—	—
Net Income, GAAP (USD)	$-7.73M	$-2.30M	—	—	$-1.30M	$-458.05K	—	—
Operating Cash Flow (USD)	$-6.76M	—	—	—	$-573.80K	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago

Conexeu Sciences Inc.

Analytical Summary

8-Year Financial Trajectory

Statement lens

Benchmark Lens

Compare CNXU with peers